Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-963272 DDI with Rosuvastatin in Healthy Participants
NCT04124003Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-963272 in Nonalcoholic steatohepatitis (NASH) and obesity, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum concentration, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration and 1 more. Started Oct 2019; status: completed.
02
Drugs
BMS-963272
03
Conditions
Nonalcoholic steatohepatitis (NASH)obesity
Beyond the preview
Go deeper on NCT04124003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124003.